Neurosciences Victoria signs three-year deal with Schering
04 July, 2002 by Melissa TrudingerNeurosciences Victoria (NSV) and Schering at the end of June announced that they had entered into a three year research collaboration focusing on drug discovery and target evaluation for neurodegenerative diseases.
Bacteria-SIDS connection identified
28 June, 2002 by Tanya HollisMonash University researchers have confirmed a link between bacterial infections and sudden infant death syndrome (SIDS).
Genesis begins trial for psoriasis treatment
28 June, 2002 by Melissa TrudingerGenesis Research and Development Corporation has commenced a Phase II clinical trial to test the efficacy of its PVAC treatment for psoriasis when administered in combination with Ultra Violet-B (UVB) light therapy.
Vision Systems buys UK biotech
27 June, 2002 by Tanya HollisVision Systems ASX: VSL) has surprised the market by buying a UK biochemical manufacturer outright.
Charity $22.5m kickstarts new Qld innovation institute
26 June, 2002 by Pete YoungThe latest gilt-edged donation to Queensland from a charity founded by US businessman Charles Feeney will kickstart construction on a $70 million Institute of Health and Biomedical Innovation.
Survey reveals how we think about being human
25 June, 2002 by Tanya HollisA survey of 7500 Australians on the issue of when an embryo is considered to be human has shown that most people do not believe a human is created at conception.
Meditech announces positive HyDOX results
07 June, 2002 by Melissa TrudingerMeditech Research has announced that its pre-clinical animal studies for anti-cancer drug HyDOX showed a three-fold reduction of heart damage.
IDT not concerned by AstraZeneca decision on cancer drug
07 June, 2002 by Tanya HollisPharmaceutical manufacturer Institute of Drug Technology may pursue direct talks with the UK developer of an early-stage anti-cancer drug after licensee AstraZeneca dumped the project.
Progen PI-88 trials proliferate
06 June, 2002 by Pete YoungAustralian biotech Progen Industries has won ethics approval to launch a Phase I human trial for its anti-cancer drug candidate PI-88 in conjunction with established chemotherapy agent Taxotere.
Psoriasis gene cream results published
05 June, 2002 by Tanya HollisA Melbourne-developed topical antisense drug has been shown to successfully penetrate human psoriasis lesions, paving the way for better treatment of the disease.
Meditech in deal with UK's SkyePharma
04 June, 2002 by Tanya HollisPerth-based Meditech Research has signed an exclusive commercial agreement with British drug company SkyePharma giving the local biotech access to a suite of new patents.
WEHI research suggests alternative MS treatment
03 June, 2002 by Melissa TrudingerResearchers at the Walter and Eliza Hall Institute have discovered that treatment with cytokine Leukaemia Inhibitory Factor (LIF) can reverse the loss of nerve cells in a mouse model of multiple sclerosis (MS).
Biotron begins cancer detection assay trials
31 May, 2002 by Melissa TrudingerA new clinical diagnostic assay for prostate cancer detection is starting clinical trials at St Vincent's Clinic in Sydney.
US cancer institute evaluating Peplin drug
31 May, 2002 by Pete YoungThe American National Cancer Institute is scheduling advanced appraisals of an Australian anti-cancer drug which has produced impressive results in preliminary trials.
Mimotopes and Baker combine on cardio treatment
28 May, 2002 by Melissa TrudingerA letter of intent to jointly develop a new class of drugs for the treatment of congestive heart failure and other cardiovascular diseases has been signed by combinatorial and medicinal chemistry company Mimotopes and the Baker Medical Research Institute.
